When STING is activated, the potent liberation of Type I IFNs and other inflammatory mediators results in tumor necrosis (19, 28), activation of antigen presenting cells (APCs) (25, 28), enhanced cross-priming of CD8+ lymphocytes and recruitment of anti-tumor lymphocytes into the tumor immune microenvironment (TIME) (19, 21, 28). The gene discussed is CD8A; the disease is neoplasm.